In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies.
Last month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, a medical oncologist from Newcastle in the UK who, in 2003, was
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
